Nupathe Inc: (NASD: PATH)
$3.14
-0.01 (-0.32%)
Volume 136,264
May 22 04:00 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 3.12 - 3.14 |
| 52wk Low - High | 2.47 - 4.59 |
| Previous Close | 3.15 |
| Avg. Volume | 143,156 |
| Industry | MED PRODUCTS |
| Market Cap | 91.57 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 0.96 |
| PE (Forward) | 0.00 |
| Current Year Est. | -1.23 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
177 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | -1.23 |
| Current Quarter Estimate | -0.19 |
| Most Accurate Estimate | -0.19 |
| Earnings ESP |
0.00% |
| Next Earnings Report Date | 08-13-2013 |
| EPS Last Year | -2.12 |
| Expected Earnings Growth | NA |
Company Description
NuPathe Inc. is a specialty pharmaceutical company focused on the development and commercialization of branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders. The Company's product candidate, Zelrix is a transdermal patch for the treatment of migraine. Zelrix actively delivers sumatriptan through the skin in a controlled manner using its proprietary SmartRelief technology. NuPathe has two other proprietary product candidates in preclinical development that address large market opportunities: NP201 for the continuous symptomatic treatment of Parkinson's disease, and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The Company is headquartered in Conshohocken, Pennsylvania.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.19 | -0.19 | -1.23 | -0.75 |
| Number of Estimates | 4 | 4 | 4 | 4 |
| Low Estimate | -0.25 | -0.25 | -1.43 | -1.33 |
| High Estimate | -0.15 | -0.16 | -1.12 | NA |
| Year Ago EPS | -0.42 | -0.42 | -2.40 | -1.23 |
| EPS Growth | 55.36% | 54.17% | 48.75% | 39.02% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| NUPATHE INC | PATH | 3.15 | |
|
| ATRICURE INC | ATRC | 8.99 | |
|
| CONCEPTUS INC | CPTS | 30.98 | |
|
| INVIVO THERAPT | NVIV | 2.90 | |
|
| TRANS1 INC | TSON | 1.59 | |
|
| ABAXIS INC | ABAX | 44.22 | |
|
| ADVAXIS INC | ADXS | 0.05 | |
|
| BAXTER INTL | BAX | 73.04 | |
|
| BIO-RAD LABS -A | BIO | 116.12 | |
|
| BIOLIFE SOL INC | BLFS | 0.38 | |
|
Sector:Medical>> Industry:MED PRODUCTS
COMPARE TICKER vs. Its Peers
Zacks Commentary
Financials
| EPS TTM | -2.12 |
| Sales | 1 |
| Net Income | -36 |
| Price/Earnings | NA |
| Price/Book | NA |
| Price/Cash Flow | NA |
| Price/Sales | NA |
News
NuPathe Announces Allowance of Additional U.S. Patent Application for NP201 - Benzinga
May 13, 2013
4 Health Care Stocks Under $10 to Watch - TheStreet.com
Apr 16, 2013
5 Reasons Not to Worry This Week - TheMotleyFool
Mar 25, 2013
CAPScall of the Week: Zogenix - TheMotleyFool
Mar 5, 2013
Kapitall Community: 10 Most Traded Stocks Of January - Kapitall
Feb 5, 2013
Benzinga`s Top Pre-Market Gainers - Benzinga
Jan 22, 2013
This Week in Biotech - TheMotleyFool
Jan 19, 2013
Deja Vu: A 10% Jump for That? - TheMotleyFool
Jan 18, 2013
Broker Recommendations
| Current ABR | 1.80 |
| ABR (Last Week) | 1.80 |
| # of recs in ABR | 5 |
| Average Target Price | 6.33 |
| Industry Rank by ABR | 177 out of 265 |
| Rank in Industry | 5 out of 73 |
